PharmaFocus Today – Page 34 – media

Eli Lilly invests $5 billion in U.S. plant to expand production of targeted cancer drugs and other therapies

On Tuesday, US Eastern Time, US pharmaceutical giant Eli LillyEli Lilly announced a $5 billion investment in a manufacturing facility in Goochland County, Virginia, to increase production of APIs and finished products for advanced therapies such as targeted cancer drugs. During U.S. trading, Eli Lilly’s stock price rose by over 2.5%. Eli Lilly stated that the new plant will be used to produce active ingredients for cancer and autoimmune disease drugs, as well as other advanced therapies. Eli Lilly emphasized that the plant will significantly enhance the local production capacity of antibody-drug conjugates (ADCs). ADCs are an emerging class of targeted therapies, often referred to as “biological missiles” in the industry. They combine monoclonal antibodies with toxic “payloads” to kill cancer cells. Currently, several pharmaceutical companies are developing or have already launched these drugs and are exploring their use in autoimmune diseases and other indications. “This is new capacity to ...
- Source: drugdu
- 129
- September 22, 2025
The investment logic of multinational pharmaceutical companies has changed

Recently, multiple sources have indicated that Bristol-Myers Squibb(BMS) will sell 60% of its stake in Shanghai Bristol-Myers Squibb Co., Ltd., and the buyer may be an affiliate of Hillhouse Capital Group. According to an email circulating online, BMS has signed an agreement to sell its 60% stake in Shanghai Bristol-Myers Squibb Pharmaceuticals Co., Ltd. and several related products manufactured and sold exclusively in mainland China to an affiliate of Hillhouse Capital. These products include Baraclude, Bufferin, Theragran, Monopril, and Velosef (Velosef). The transaction is expected to close in early 2026, and the specific amount was not disclosed. BMS stated that this divestiture will help it focus resources on core areas and optimize its business layout. BMS divests major assets According to data, in 1982, Shanghai Bristol-Myers Squibb was established by the American company Bristol-Myers Squibb and Shanghai Pharmaceuticals, the predecessor of Shanghai Pharmaceuticals Group.It was established as a joint venture ...
- Source: drugdu
- 145
- September 22, 2025
Changchun High-Tech invested nearly 1.5 billion yuan to introduce three new drugs

On September 17, Changchun High-Tech announced that its holding subsidiary Jinsai Pharmaceuticals had reached an allergen-specific immunotherapy (AIT) product cooperation with Denmark’s ALK-Abelló A/S (ALK). The company will jointly develop and commercialize ALK’s house dust mite (HDM) allergen-specific immunotherapy products in China, and obtain exclusive agency rights for three products independently developed by ALK in mainland China. According to the agreement, Jinsai Pharmaceutical will pay an initial payment of €32.7 million and a €40 million registration milestone payment for the dust mite allergen sublingual tablet (ACARIZAX) in China. Jinsai Pharmaceutical will also cover the majority of future Phase III bridging clinical study and registration costs for adult and adolescent indications, while both parties will each cover 50% of the clinical study and registration costs for pediatric indications. Furthermore, depending on the sales performance of these products in the Chinese market, Jinsai Pharmaceutical may make subsequent sales milestone payments of €105 ...
- Source: drugdu
- 153
- September 22, 2025
WALVAX’s clinical application for freeze-dried herpes zoster virus mRNA vaccine has been accepted

On September 19, WALVAX(300142) announced that its subsidiaries, Beijing Watson Innovation Biotechnology Co., Ltd., Yunnan Vaccine Laboratory Co., Ltd., and Yuxi WALVAXtechnology Co., Ltd., jointly developed with Fudan University and Shanghai Blue Magpie Biopharmaceutical Co., Ltd., have submitted their clinical trial application to the National Medical Products Administration and received a “Notice of Acceptance.” The vaccine’s primary function is to stimulate immunity against the herpes zoster virus and is intended for the prevention of shingles. The announcement mentioned that the acceptance numbers of the vaccine application are CXSL2500804 and CXSL2500805, and the registration classification is a preventive biological product.1.2. According to relevant regulations, after an application is accepted, it must undergo a technical review by the Center for Drug Evaluation of the National Medical Products Administration and obtain approval before clinical trials can begin. By mid-2025, WALVAX achieved revenue of 1.154 billion yuan and net profit attributable to shareholders of ...
- Source: drugdu
- 107
- September 22, 2025
New neuro-sensing technique captures brainwaves from within veins

Researchers at The University of Osaka have developed a groundbreaking, minimally invasive method for recording brain activity through blood vessels. This technique could potentially transform the diagnosis and treatment of neurological conditions like epilepsy and paving the way for advanced brain-computer interfaces. It eliminates the need for invasive open-brain surgery, offering a safer and more accessible way to monitor and stimulate brain function. Current methods for directly measuring brain activity require invasive procedures, either removing part of the skull to place electrodes on the brain surface or inserting electrodes directly into brain tissue. While non-invasive methods like EEG exist, they lack the precision needed for detailed analysis. This new method bridges the gap, offering high-fidelity recordings without the risks associated with traditional invasive approaches. The research team, led by Professor Takufumi Yanagisawa used a catheter to insert ultra-thin wire electrodes into the cortical and deep veins of pig brains. They ...
- Source: drugdu
- 125
- September 22, 2025
Why Mosquitos Might Be Attracted To You

By Deanna Neff HealthDay ReporterSATURDAY, Sept. 20, 2025 (HealthDay News) — Researchers in the Netherlands turned a major music festival into an unexpected laboratory to investigate a question that has long puzzled scientists and bug-bitten individuals alike: What makes some people more irresistible to mosquitoes than others? For three consecutive days at the Lowlands festival in Biddinghuizen, Netherlands, scientists set up a unique pop-up research site inside a series of shipping container laboratories. Instead of waiting for their favorite band, hundreds of festivalgoers lined up to volunteer for the “Mosquito Magnet Trial,” a study designed to measure their personal attractiveness to the insects. Inside the make-shift lab from 9 a.m. to 10 p.m. each day, groups of participants rested their arms against transparent acrylic boxes that had caged mosquitoes. As the insects responded to the human scent, a camera and computer system recorded mosquito movements and calculated a unique attraction ...
- Source: drugdu
- 86
- September 22, 2025
Zhengda Tianqing targets 9.2 billion yuan drug

On September 15, the injectable degarelix acetate (Qinglishu) independently developed by Zhengda Tianqing obtained the drug registration certificate issued by the National Medical Products Administration (NMPA) for use in prostate cancer patients who require androgen deprivation therapy. As the original drug in this category, degarelix acetate (fermonger)’s global sales exceeded US$1.3 billion (approximately RMB 9.2 billion) in 2024. Is Zhengda Tianqing, the “pioneer in anti-tumor innovation”, brewing a blockbuster drug? 01 Approved for listing in three locations The original developer of Degarelix Acetate for Injection is Ferring Pharmaceuticals. As a selective gonadotropin-releasing hormone receptor (GnRHR) antagonist, the clinical value of Degarelix Acetate in the treatment of prostate cancer has long been recognized worldwide. This drug can effectively reduce the release of gonadotropin and testosterone by reversibly binding to the GnRH receptors in the pituitary gland, thereby inhibiting the growth and spread of prostate cancer cells from the root. Especially in ...
- Source: drugdu
- 198
- September 18, 2025
Announcement on the Holding Subsidiary Obtaining Medical Device Registration Certificate

September 17th, Meikang BioAccording to the announcement, the company’s holding subsidiary Jiangxi Meikang Shengde Biotechnology Co., Ltd. recently obtained the ” Medical Device Certificate of the People’s Republic of China” issued by the Jiangxi Provincial Drug Administration.Registration Certificate ( In Vitro DiagnosticThe product names are: tissue plasminogen activator-inhibitor 1 complex detection kit (chemiluminescent immunoassay), thrombin-antithrombin complex detection kit (chemiluminescent immunoassay), thrombomodulin detection kit (chemiluminescent immunoassay), plasmin-α2 plasmin inhibitor complex detection kit (chemiluminescent immunoassay). https://finance.eastmoney.com/a/202509173516207639.html
- Source: drugdu
- 118
- September 18, 2025
Plans to invest RMB 42.74 million in Wuhan Huajiyuan to advance clinical trials of the therapeutic antihypertensive vaccine (HJY-ATRQβ-001) project

Meijing AI News, September 17, Saili Medical(603716.SH) announced plans to increase capital by 42.7429 million yuan in its subsidiary, Wuhan Huajiyuan Biotechnology Development Co., Ltd. Upon completion of the capital increase, the company’s stake in Wuhan Huajiyuan will increase to 41%. Concurrently, the company’s actual controller, Wen Wei, plans to acquire a 10% stake in Wuhan Huajiyuan shareholder Sun Danping for 27.2 million yuan, at a post-capital valuation of 272 million yuan. The company and its actual controller, Wen Wei, will contribute a total of 69.9429 million yuan in this transaction. The target company will be consolidated as a controlled subsidiary of the company in 2026. All parties agreed to actively advance the various phases of clinical trials for the target company’s therapeutic antihypertensive vaccine (HJY-ATRQβ-001) project and work together to develop the target company’s business. Upon completion of the capital increase, all parties pledged to actively conduct research and ...
- Source: drugdu
- 116
- September 18, 2025
Eli Lilly wins again! Oral weight loss drug outperforms oral sirolimus in head-to-head tria

Eli LillyTwo star weight loss pillsThe “one-on-one” battle has spread to the field of oral drugs, and the pressure has been put on Novo Nordisk.. On September 17, Eli Lilly announced positive top-line results from the Phase III ACHIEVE-3 study. The 52-week study compared orforglipron (12 mg and 36 mg) with oral semaglutide (7 mg and 14 mg) in terms of glycemic control and weight loss across four active treatment groups. At 52 weeks, orforglipron achieved its primary endpoint and all key secondary endpoints across all dose groups, demonstrating superiority over oral semaglutide in terms of improvements in glycated hemoglobin (A1C) and weight. Orforglipron is an oral small molecule GLP-1 receptor agonist from Eli Lilly , and Rybelsus is an oral GLP-1 drug from Novo Nordisk . The aforementioned study was a head-to-head comparison. A head-to-head study can be considered a direct comparison of the two drugs’ efficacy and safety. ...
- Source: drugdu
- 159
- September 18, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.